William Reid, a Director at EMCOR Group Inc (EME), sold 2,000 shares of the company on May 11, 2026, reducing his holding to 10,149 shares. This transaction is part of a pattern of 11 insider sells and no buys for EME over the past year. The stock is currently trading at $925.78, indicating it is significantly overvalued with a price-to-GF-Value ratio of 1.67, and its P/E ratio of 30.96 is higher than both the industry median and its historical median.

Costco is reportedly testing chicken strips in six Chicago locations, which may replace the calzone, a long-time fan favorite. The baked chicken strips, priced at $6.99 for five pieces and sweet honey mustard, contain 1,640 calories. This change follows another recent adjustment to Costco's $1.50 hot dog combo, which now includes Kirkland Signature water instead of Coca-Cola products in some areas.

Delta Air Lines (DAL) stock, currently trading at US$71.05, has shown positive momentum with a 42.15% one-year total return. While one valuation narrative suggests the stock is 12% overvalued with a fair value of $63.21 due to stretched pricing, another Discounted Cash Flow (DCF) model indicates a 33% discount, placing its fair value at $106.02, highlighting a split in expert opinion regarding its true value. Investors are advised to review both perspectives and consider key rewards and warning signs before making investment decisions.

This page provides financial information, specifically "Cash from investing activities," for D.R. Horton, Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S (TSX: DHI). It includes data for various periods, showing value, change, and percentage change. The content highlights financial metrics related to the company's investment activities.

NetApp has announced new data management capabilities optimized for Red Hat OpenShift, designed to enhance resilience and scalability for virtualized environments both on-premises and in the cloud. These updates aim to improve the speed and predictability of backup and recovery, addressing challenges faced by growing virtualized infrastructures where traditional backup methods become inefficient. The collaboration focuses on delivering an enterprise-ready Kubernetes stack with features like block-level change tracking, simplified disaster recovery, and enhanced hybrid/multicloud consistency.

The Schall Law Firm is investigating Willis Towers Watson Public Limited Company (NASDAQ: WTW) for potential securities law violations after the company reported a decline in operating margin and low organic revenue growth for Q1 2026, leading to an almost 11.7% drop in share price. The firm encourages affected shareholders to participate in the fraud investigation.

Joseph Sala, Group Vice President at Exponent Inc, sold 2,066 shares of the company on May 13, 2026, and now holds no shares. This sale is part of a trend of 14 insider sells and no buys at Exponent Inc over the past year. The stock is currently trading at $56.66, which is significantly undervalued compared to its GF Value of $92.37.

Elanco has agreed to a $9.3 million settlement with consumers to resolve antitrust allegations related to its flea and tick prevention products. While Elanco disputes the allegations, the settlement aims to resolve claims that the company used anti-competitive tactics. This development follows a period of scrutiny over the pharmaceutical industry's practices.

A lawsuit deadline of May 18, 2026, is approaching for investors in Gemini Space Station, Inc. (NASDAQ: GEMI) due to alleged securities law violations. The lawsuit claims that Gemini's IPO documents contained misleading statements and that the company made false statements regarding its business, operations, and prospects between September 12, 2025, and February 17, 2026. Investors who purchased shares during this period are encouraged to contact the Shareholders Foundation for options.

Femasys Inc. filed an 8-K to present an updated corporate presentation detailing its women's reproductive health portfolio and growth strategy. The presentation focuses on FemaSeed for in-office fertility treatment and FemBloc, a non-surgical permanent birth control undergoing a U.S. pivotal trial. The company highlights the significant unmet market needs in fertility and contraception, presenting clinical data for both products and outlining their commercialization plans and economic benefits for OB/GYN practices.